Profile data is unavailable for this security.
About the company
ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.
- Revenue in CAD (TTM)428.00k
- Net income in CAD-36.83m
- Incorporated1944
- Employees2.00
- LocationZYUS Life Sciences Corp204 - 407 Downey RoadSASKATOON S7N 4L8CanadaCAN
- Phone+1 (306) 242-2357
- Fax+1 (416) 368-4440
- Websitehttps://www.zyus.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nurexone Biologic Inc | 0.00 | -5.62m | 37.67m | 8.00 | -- | 10.74 | -- | -- | -0.1081 | -0.1081 | 0.00 | 0.052 | 0.00 | -- | -- | -- | -183.97 | -213.78 | -235.34 | -596.97 | -- | -- | -- | -- | -- | -187.27 | 0.0096 | -- | -- | -- | 55.45 | -- | -- | -- |
| Avicanna Inc | 24.87m | -7.44m | 40.62m | 38.00 | -- | 1,130.84 | -- | 1.63 | -0.0804 | -0.0804 | 0.2714 | 0.0003 | 1.20 | 2.95 | 9.32 | 654,600.00 | -35.85 | -67.17 | -267.70 | -167.73 | 48.66 | 46.36 | -29.90 | -368.82 | 0.3316 | -8.88 | 0.1645 | -- | 314.82 | 169.57 | 40.67 | -- | -32.29 | -- |
| Microbix Biosystems Inc | 23.36m | 5.08m | 47.07m | 69.00 | 9.34 | 1.68 | 7.13 | 2.01 | 0.0369 | 0.0369 | 0.1695 | 0.205 | 0.6488 | 1.63 | 6.35 | -- | 14.10 | -0.9729 | 16.10 | -1.17 | 57.21 | 52.30 | 21.73 | -1.55 | 4.89 | 5.93 | 0.1849 | -- | -13.43 | 5.71 | -102.21 | -- | -3.56 | -- |
| KDA Group Inc | 204.14k | -876.18k | 48.26m | -- | -- | 3.35 | -- | 236.42 | -0.0027 | 0.0783 | 0.0013 | 0.0821 | 0.008 | -- | 0.0835 | -- | -4.63 | -17.96 | -8.47 | -44.69 | 33.32 | 26.76 | -574.97 | -28.00 | -- | -7.08 | 0.0606 | -- | -22.20 | -62.03 | 106.88 | -- | 31.67 | -- |
| MustGrow Biologics Corp | 4.71m | -423.96k | 52.14m | 0.00 | -- | 14.47 | -- | 11.07 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -23.05m | 55.30m | 12.00 | -- | 1.90 | -- | -- | -0.2044 | -0.2044 | 0.00 | 0.2585 | 0.00 | -- | -- | 0.00 | -53.45 | -107.22 | -57.45 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
| Helix Biopharma Corp. | 0.00 | -6.14m | 63.24m | 9.00 | -- | -- | -- | -- | -0.1478 | -0.1478 | 0.00 | -0.0079 | 0.00 | -- | -- | 0.00 | -449.73 | -261.49 | -2,225.00 | -- | -- | -- | -- | -- | -- | -265.96 | -- | -- | -- | -- | 4.16 | -- | -28.36 | -- |
| ZYUS Life Sciences Corp | 428.00k | -36.83m | 68.41m | 2.00 | -- | 4.20 | -- | 159.83 | -0.5247 | -0.5247 | 0.0061 | 0.2192 | 0.0074 | 0.075 | 0.5757 | -- | -63.34 | -57.88 | -88.37 | -71.19 | 46.50 | -16.16 | -8,604.67 | -10,367.37 | 0.1593 | -35.94 | 0.3955 | -- | 17.79 | 213.99 | -72.73 | -- | -- | -- |
| Covalon Technologies Ltd | 29.20m | -823.40k | 84.95m | -- | -- | 3.70 | 675.59 | 2.91 | -0.0335 | -0.0335 | 1.18 | 0.8786 | 1.10 | 1.77 | 5.15 | -- | -3.11 | -18.06 | -3.72 | -27.10 | 56.45 | 51.89 | -2.82 | -27.06 | 3.72 | -21.12 | 0.0474 | -- | 46.56 | -0.096 | 51.79 | -- | 12.21 | -- |
| Oncolytics Biotech Inc | 0.00 | -28.02m | 99.38m | 29.00 | -- | 5.41 | -- | -- | -0.3827 | -0.3827 | 0.00 | 0.2383 | 0.00 | -- | -- | -- | -87.53 | -81.99 | -101.45 | -97.25 | -- | -- | -- | -- | -- | -- | 0.0575 | -- | -- | -- | -11.75 | -- | -40.52 | -- |
